Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Hansson

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
The Lancet. Haematology|May 4, 2020
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 studyMichele Cavo, Francesca Gay, Meral Beksac, et al.
Nature Communications|January 12, 2019
Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myelomaMolly Went, Amit Sud, Asta Försti, et al.
Nature Communications|September 15, 2018
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myelomaMolly Went, Amit Sud, Asta Försti, et al.
BMC Cardiovascular Disorders|October 31, 2019
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9Amand F Schmidt, Michael V Holmes, David Preiss, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
The Lancet. Haematology|May 4, 2020
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 studyMichele Cavo, Francesca Gay, Meral Beksac, et al.
Nature Communications|January 12, 2019
Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myelomaMolly Went, Amit Sud, Asta Försti, et al.
Nature Communications|September 15, 2018
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myelomaMolly Went, Amit Sud, Asta Försti, et al.
BMC Cardiovascular Disorders|October 31, 2019
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9Amand F Schmidt, Michael V Holmes, David Preiss, et al.
Pageof 9